Syngene International Ltd

Syngene Intl. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Syngene International Ltd

₹ 720 -0.07%
05 Jun 3:00 p.m.
syngeneintl.com BSE: 539268 NSE : SYNGENE
About

Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be an integrated service provider offering end-to-end drug discovery, development, and manufacturing services on a single platform (CRAMS). Total research & manufacturing infrastructure for the company is spread across 1.9 million square feet across locations. [1]

Key Points

Business Footprint:[1][2]
The company caters to diverse end-user industries like Pharmaceuticals, Animal Health, Agrochemicals, Consumer Packaged Goods, Chemicals/Polymers.
It has 400+ active customers with engagements with 8 out of the top 10 global pharma companies. The company holds 400+ patents jointly with clients and has a base of 5200+ scientists.

Website BSE NSE
  • Market Cap ₹ 28,945 Cr.
  • Current Price ₹ 720
  • High / Low ₹ 730 / 521
  • Stock P/E 61.2
  • Book Value ₹ 90.2
  • Dividend Yield 0.07 %
  • ROCE 15.1 %
  • ROE 13.7 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has reduced debt.
  • Company's median sales growth is 19.4% of last 10 years

Cons

  • Stock is trading at 8.03 times its book value
  • Promoter holding has decreased over last quarter: -9.98%
  • Dividend payout has been low at 6.93% of profits over last 3 years
  • Working capital days have increased from 22.3 days to 90.0 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2020 Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023
607 420 517 584 658 594 610 640 759 644 768 787 994
404 296 362 408 443 429 432 437 509 473 552 556 678
Operating Profit 204 124 155 176 215 164 177 203 249 172 216 230 316
OPM % 34% 30% 30% 30% 33% 28% 29% 32% 33% 27% 28% 29% 32%
20 15 14 17 53 12 -18 13 15 16 15 17 23
Interest 9 7 7 7 7 8 1 9 6 9 12 14 10
Depreciation 62 66 69 70 70 75 76 78 80 86 90 95 88
Profit before tax 153 66 94 116 192 94 82 128 178 92 129 139 241
Tax % 21% 12% 11% 12% 16% 18% 19% 19% 17% 20% 21% 21% 21%
Net Profit 120 58 84 102 160 77 66 103 147 73 102 110 189
EPS in Rs 3.00 1.44 2.09 2.54 4.01 1.92 1.66 2.58 3.67 1.82 2.53 2.73 4.71
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
417 550 700 860 1,107 1,201 1,423 1,826 2,012 2,179 2,601 3,194
280 382 485 579 727 816 950 1,290 1,395 1,504 1,806 2,259
Operating Profit 137 168 214 281 380 385 473 536 617 676 795 934
OPM % 33% 31% 31% 33% 34% 32% 33% 29% 31% 31% 31% 29%
2 4 8 12 6 94 53 75 153 94 20 71
Interest 10 6 0 8 8 18 23 32 35 28 24 45
Depreciation 55 60 66 81 97 114 131 164 219 274 310 359
Profit before tax 74 106 157 204 281 346 372 414 516 467 482 601
Tax % 4% 4% 14% 14% 14% 17% 18% 20% 20% 14% 18% 21%
Net Profit 71 102 135 175 241 287 305 331 412 404 394 473
EPS in Rs 7.37 9.43 12.45 4.38 6.02 7.18 7.63 8.27 10.29 10.09 9.83 11.78
Dividend Payout % 0% 0% 0% 239% 8% 7% 7% 3% 0% 0% 10% 11%
Compounded Sales Growth
10 Years: 19%
5 Years: 18%
3 Years: 17%
TTM: 23%
Compounded Profit Growth
10 Years: 17%
5 Years: 10%
3 Years: 10%
TTM: 14%
Stock Price CAGR
10 Years: %
5 Years: 20%
3 Years: 25%
1 Year: 34%
Return on Equity
10 Years: 17%
5 Years: 15%
3 Years: 14%
Last Year: 14%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
24 26 26 199 200 200 200 200 400 400 401 401
Reserves 273 492 633 646 825 1,213 1,520 1,767 1,774 2,418 2,891 3,218
97 4 155 155 891 806 787 813 773 893 1,022 639
193 201 377 422 440 555 681 922 1,215 1,166 1,247 1,590
Total Liabilities 587 724 1,191 1,422 2,356 2,775 3,188 3,702 4,162 4,878 5,561 5,848
383 381 394 503 580 810 1,030 1,377 2,020 2,201 2,393 2,260
CWIP 11 9 45 105 237 175 155 274 234 237 346 126
Investments 0 69 352 146 277 540 158 716 777 702 1,034 941
193 265 399 667 1,262 1,249 1,845 1,336 1,132 1,737 1,787 2,521
Total Assets 587 724 1,191 1,422 2,356 2,775 3,188 3,702 4,162 4,878 5,561 5,848

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
122 104 300 18 308 398 446 630 677 698 582 838
-20 -150 -375 16 -753 -470 -350 -646 -424 -629 -611 -688
-70 21 155 -10 716 -81 -79 -72 -226 58 -31 -340
Net Cash Flow 32 -26 80 24 272 -153 17 -88 28 127 -60 -190

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 38 51 49 76 61 60 68 68 72 79 71 55
Inventory Days 48 45 28 59 44 37 82 30 18 41 87 141
Days Payable 209 208 146 106 87 116 194 154 157 166 115 110
Cash Conversion Cycle -123 -112 -68 29 18 -19 -44 -56 -67 -45 44 86
Working Capital Days -24 5 -61 -6 -10 -14 -28 -65 -115 -19 -4 90
ROCE % 22% 25% 23% 23% 20% 18% 16% 17% 17% 14% 13% 15%

Shareholding Pattern

Numbers in percentages

16 Recently
Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023
70.65 70.61 70.59 70.58 70.43 70.42 70.41 70.41 70.29 64.86 64.86 54.88
13.10 14.58 14.32 14.25 14.42 14.09 13.84 13.69 14.15 16.79 16.87 23.31
9.63 6.68 5.78 5.27 4.75 4.80 4.41 4.41 4.18 6.75 7.03 10.71
5.78 7.39 8.58 9.19 9.49 9.82 10.61 10.81 10.56 11.11 10.77 10.65
0.85 0.74 0.73 0.71 0.90 0.86 0.72 0.68 0.83 0.49 0.47 0.46

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls